Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of transcatheter arterial chemoembolization using combination of epirubicin and miriplatin for hepatocellular carcinoma -Prospective comparative study with transcatheter arterial chemoembolization using epirubicin-

Trial Profile

Efficacy and safety of transcatheter arterial chemoembolization using combination of epirubicin and miriplatin for hepatocellular carcinoma -Prospective comparative study with transcatheter arterial chemoembolization using epirubicin-

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Epirubicin (Primary) ; Miriplatin (Primary) ; Ethiodized oil
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2012 New trial record
    • 19 Oct 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top